Kite On Course For FDA Filing On Positive CAR-T Durability Data

Kite Pharma is looking stronger than ever in the race to get a CAR-T product onto the market following positive topline results from a primary six-month analysis for KTE-C19 in aggressive NHL (ZUMA-1).